Tesamorelin Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on Tesamorelin for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

Tesamorelin is classified as a Stabilised GHRH analogue (trans-3-hexenoyl modification at the N-terminus). Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | Tesamorelin | | --- | --- | | Classification | Stabilised GHRH analogue (trans-3-hexenoyl modification at the N-terminus) | | Serum half-life | Serum half-life of approximately 26–38 minutes in published clinical PK studies — longer than sermorelin due to enzymatic stabilisation. | | Tmax | Tmax of ~0. | | Validated routes | Subcutaneous administration is the only validated route in the published clinical literature. | | Bioavailability | Subcutaneous bioavailability ~4% (low absolute), but reproducible pharmacodynamic GH/IGF-1 response across the published clinical literature. | | Clearance | Hepatic and renal clearance of degradation products; no clinically significant accumulation with once-daily dosing. |

Serum Half-Life

Serum half-life of approximately 26–38 minutes in published clinical PK studies — longer than sermorelin due to enzymatic stabilisation.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For Tesamorelin, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of ~0.15 hours (~9 minutes) after subcutaneous administration; peak GH response at ~30 minutes; IGF-1 elevations persist for ~24 hours.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous administration is the only validated route in the published clinical literature.

Bioavailability across routes: Subcutaneous bioavailability ~4% (low absolute), but reproducible pharmacodynamic GH/IGF-1 response across the published clinical literature.

Clearance & Metabolism

Hepatic and renal clearance of degradation products; no clinically significant accumulation with once-daily dosing.

Key Pharmacokinetic Takeaways

• FDA-approved GHRH analogue with the most robust clinical PK/PD literature of any peptide GH stimulator
• Once-daily subcutaneous dosing is supported by 24-hour IGF-1 elevations in published PK datasets
• Resistance to DPP-IV degradation drives its longer half-life versus sermorelin
• Pharmacokinetic stability supports reproducible body-composition endpoints in research models

Frequently Asked Questions

What is the half-life of Tesamorelin? Serum half-life of approximately 26–38 minutes in published clinical PK studies — longer than sermorelin due to enzymatic stabilisation.

How quickly does Tesamorelin reach peak concentration? Tmax of ~0.15 hours (~9 minutes) after subcutaneous administration; peak GH response at ~30 minutes; IGF-1 elevations persist for ~24 hours.

Which routes of administration are validated in published research? Subcutaneous administration is the only validated route in the published clinical literature.

Does Tesamorelin accumulate with repeat dosing? Hepatic and renal clearance of degradation products; no clinically significant accumulation with once-daily dosing. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for Tesamorelin? Subcutaneous bioavailability ~4% (low absolute), but reproducible pharmacodynamic GH/IGF-1 response across the published clinical literature.

Related Research

• Reconstitution & storage protocols — see the Tesamorelin reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the Tesamorelin dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the Tesamorelin mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*